First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Factor XI Monoclonal Antibody SHR-2004 in Healthy Subjects

待确认 20 由随风发布于 2026/4/3 9:14:41

DOI:10.1182/blood-2023-173295
作者：Tingting Ma, B. Cao, Zuyi Weng, Yanli Dong, Shimin An, Lei Huang, Yuanxun Yang, Yan Geng, Hui Lin, Yuqi Wang, Pinhao Xie, Kai Shen, Juan Li
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Introduction: Thromboembolic disease is a major global health problem. Inhibition of coagulation factor XI (FXI) is a novel strategy for the prevention and treatment of thrombotic diseases w

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

14小时前

达姆

202604030927504403986.pdf

14小时前

Book学术机器人

2026/4/3 9:14:41 未找到该文献，机器人已退出，请等待人工下载

2026/4/3 9:14:41 Book学术AI机器人收到请求，开始寻找文献

2026/4/3 9:14:41 已向机器人发送请求

14小时前

随风发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierNeurointerventions on two generations of angiography systems: Recent systems reduce radiation exposure by half